IL324314A - מעכב egfr לטיפול בסרטן המכיל מוטציות egfr שאינן טיפוסיות - Google Patents

מעכב egfr לטיפול בסרטן המכיל מוטציות egfr שאינן טיפוסיות

Info

Publication number
IL324314A
IL324314A IL324314A IL32431425A IL324314A IL 324314 A IL324314 A IL 324314A IL 324314 A IL324314 A IL 324314A IL 32431425 A IL32431425 A IL 32431425A IL 324314 A IL324314 A IL 324314A
Authority
IL
Israel
Prior art keywords
egfr
cancer
individual
compound
salt
Prior art date
Application number
IL324314A
Other languages
English (en)
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Publication of IL324314A publication Critical patent/IL324314A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL324314A 2023-05-05 2025-10-29 מעכב egfr לטיפול בסרטן המכיל מוטציות egfr שאינן טיפוסיות IL324314A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363464424P 2023-05-05 2023-05-05
US202363591656P 2023-10-19 2023-10-19
PCT/US2024/027642 WO2024233313A1 (en) 2023-05-05 2024-05-03 Egfr inhibitor for treating cancers comprising atypical egfr mutations

Publications (1)

Publication Number Publication Date
IL324314A true IL324314A (he) 2025-12-01

Family

ID=91302472

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324314A IL324314A (he) 2023-05-05 2025-10-29 מעכב egfr לטיפול בסרטן המכיל מוטציות egfr שאינן טיפוסיות

Country Status (7)

Country Link
EP (1) EP4704848A1 (he)
KR (1) KR20260006641A (he)
CN (1) CN121175049A (he)
AU (1) AU2024267333A1 (he)
IL (1) IL324314A (he)
MX (1) MX2025012495A (he)
WO (1) WO2024233313A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026080372A1 (en) * 2024-10-07 2026-04-16 Oric Pharmaceuticals, Inc. Treatment of cancers comprising egfr extracellular and transmembrane mutations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
JP2001524926A (ja) 1991-09-18 2001-12-04 アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ オリゴマーの雑多ライブラリーの集合体を合成する方法
DE69233501T2 (de) 1991-11-22 2006-02-23 Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara Kombinatorische Strategien für die Polymersynthese
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
SI1606288T1 (sl) 2003-03-25 2009-10-31 Fournier Lab Sa Derivati benzensulfonamida, postopek za njihovo pripravo in njihova uporaba za zdravljenje bolečine
AU2020240382B2 (en) 2019-03-19 2022-08-25 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
TWI867047B (zh) * 2020-09-18 2024-12-21 南韓商沃若諾伊公司 雜芳基衍生物、其製備方法、及含彼作為活性成份之藥學組成物
CN120035590A (zh) * 2022-11-03 2025-05-23 株式会社沃若诺伊 Egfr抑制剂的延胡索酸盐、酒石酸盐、苹果酸盐和柠檬酸盐
EP4611902A1 (en) * 2022-11-03 2025-09-10 Oric Pharmaceuticals, Inc. Malonate and glycolate salts of an egfr inhibitor

Also Published As

Publication number Publication date
EP4704848A1 (en) 2026-03-11
CN121175049A (zh) 2025-12-19
MX2025012495A (es) 2026-02-03
WO2024233313A1 (en) 2024-11-14
KR20260006641A (ko) 2026-01-13
AU2024267333A1 (en) 2025-11-06

Similar Documents

Publication Publication Date Title
KR102857219B1 (ko) 암의 치료 또는 예방용 의약
EP3733187B1 (en) Chiral diaryl macrocycle and use thereof in the treatment of cancer
KR20230069983A (ko) Cdk4 억제제의 고체 형태
IL296835A (he) תהליך להכנת מעכב parp, צורות גבישיות ושימושיהן
IL281344B2 (he) שילוב של adagrasib ו-cetuximab לטיפול בסרטן
IL324314A (he) מעכב egfr לטיפול בסרטן המכיל מוטציות egfr שאינן טיפוסיות
Jiang et al. Discovery of novel phenoxyaryl pyridones as bromodomain and extra-terminal domain (BET) inhibitors with high selectivity for the second bromodomain (BD2) to potentially treat acute myeloid leukemia
US20230248709A1 (en) Dosage Regimen for the Treatment of Cancer
AU2022203204A1 (en) Use of heterocyclic pdk1 inhibitors
KR20250093563A (ko) Egfr 억제제의 말론산염 및 글라이콜산염
KR20250097933A (ko) Egfr 억제제의 퓨마르산염, 타타르산염, 말산염, 및 시트르산염
JP2024506684A (ja) Ｐａｒｐ７阻害物質の投与レジメン
Yuan et al. Pioneering 4, 11-Dioxo-4, 11-dihydro-1 H-anthra [2, 3-d] imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy
IL278596B1 (he) מעכבים של ras אונקופרוטאין, שיטות להכנה ושיטות לשימוש בהם
IL295938A (he) שימושים טיפוליים של תרכובות מקרוציקליות
JP2023509845A (ja) 金属塩及びその使用
WO2026080372A1 (en) Treatment of cancers comprising egfr extracellular and transmembrane mutations
US20250188083A1 (en) Modulators of Histone Acetyltransferase 1 and Methods of Treatment Thereof
WO2026080869A1 (en) Macrocyclic ras inhibitors
JP2025528490A (ja) ヘテロアリールオキシナフタレン系化合物の使用
JP2018526392A (ja) キノキサリニル−ピペラジンアミドの使用方法